Fortress Biotech, Inc. - 31 Dec 2024 Form 4 Insider Report for Checkpoint Therapeutics, Inc. (CKPT)

Role
10%+ Owner
Signature
/s/ Samuel Berry, Attorney-in-Fact
Issuer symbol
CKPT
Transactions as of
31 Dec 2024
Net transactions value
$0
Form type
4
Filing time
03 Jan 2025, 16:15:16 UTC
Previous filing
01 Oct 2024
Next filing
27 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CKPT COMMON STOCK, PAR VALUE $0.0001 Award $0 +81,407 +2.2% $0.000000 3,816,941 31 Dec 2024 Direct F1
transaction CKPT COMMON STOCK, PAR VALUE $0.0001 Award $0 +2,386,808 +63% $0.000000 6,203,749 01 Jan 2025 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. These shares were granted by the Issuer to the Reporting Person following the exercise of warrants.
F2 The Reporting Person is entitled to an annual equity fee grant from the issuer of a number of shares of the Issuer's Common Stock equal to 2.5% of the Issuer's fully diluted outstanding capitalization on December 31. These shares were granted by the Issuer to the Reporting Person for the 2024 annual equity fee grant.